With the biggest dissident shareholders in favor of the new deal, we expect the transaction to be consummated without further disruptions.

We don't have a consummated deal yet. It's just too early in the game.

We don't expect to disclose any further developments until the board of directors has approved a definitive transaction.

It was a solid in-line quarter. Expenses were a bit lighter than expected and that's what gave them the beat.

The stock is really hard to call right now because it's still expensive. To get excited about it you've got to believe that there is another shoe to drop for one of the big drugs.

They've got until Thanksgiving or mid-November.